Clinical trialCLINICALTRIALSMay 7
Trial Results Posted: Calcitriol Monotherapy for X-Linked Hypophosphatemia (NCT03748966)
Researchers at Massachusetts General Hospital completed a small study testing whether a vitamin D medication called calcitriol could help people with X-linked hypophosphatemia (XLH), a rare genetic condition that causes weak bones and low phosphate levels in the blood. Sixteen children and adults took calcitriol alone for one year to see if it could improve their phosphate levels and bone strength without causing kidney problems. The study also looked at whether the treatment helped children grow taller.
WHY IT MATTERSThis completed trial tested a simpler treatment approach for XLH using calcitriol monotherapy, which could potentially reduce the pill burden for patients who typically need both calcitriol and phosphate supplements.